Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

During the preparation of its financial statements for the year-end December 31, 2015, on March 7, 2016, Bionik Laboratories Corp. (the “Company”) was advised by MNP LLP, its independent registered public accounting firm, to re-evaluate its accounting relating to the common stock purchase warrants issued in 2015 as part of the Company’s 2015 private placement (“2015 Warrants”), and to consider restating its previously issued reviewed, unaudited condensed consolidated financial statements (the “Financial Statements”) included in the Company’s Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2015, June 30, 2015 and September 30, 2015 (the “Quarterly Reports”).

The 2015 Warrants contain price protection provisions whereby the strike price is reduced upon certain Company issuances of equity at a price below the strike price of the 2015 Warrants. These price protection provisions require the 2015 Warrants to be classified as derivative liabilities and recorded at fair value. The Company accounted for the 2015 Warrants in the Quarterly Reports as equity. Additionally, in periods subsequent to issuance, changes in the fair value of the 2015 Warrants should be recorded as other income or expense in the consolidated statements of operations. These items are non-cash items and accordingly have no impact on net cash used in operating activities on the consolidated statements of cash flows.

The Company’s management promptly engaged outside advisors to consult on this matter, including a Big 4 accounting firm, and on March 9, 2016, management, with and upon advice of such advisors and further discussions with its auditors, determined that the Financial Statements included in the Quarterly Reports should no longer be relied upon and will be restated due to non-cash errors identified in the accounting for the 2015 Warrants.

The Company intends to file restated Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2015, June 30, 2015 and September 30, 2015 as soon as practicable.

In addition, the Company is reassessing its previous conclusions regarding the effectiveness of its internal control over financial reporting and disclosure controls and procedures.

The Company’s senior management has discussed the matters disclosed in this Item 4.02 of this Current Report with MNP LLP, the Company’s independent registered public accounting firm.

Caution Regarding Forward-Looking Statements

This Current Report on Form 8-K includes information that constitutes forward-looking statements. These forward-looking statements are based on Bionik’s current beliefs, assumptions and expectations regarding future events, which in turn are based on information currently available to the Company. Such forward-looking statements include statements regarding materiality or significance, the quantitative effects of the consolidated restated financial statements, and any anticipated conclusions of the Board of Directors or the Company’s management with respect to the matters relating to the Company’s accounting, including the restatement of the interim consolidated financial statements as of and for the quarterly periods ended March 31, 2015, June 30, 2015 and September 30, 2015. By their nature, forward-looking statements address matters that are subject to risks and uncertainties. A variety of factors could cause actual events and results, as well as the Company’s expectations regarding materiality or significance, the restatement’s quantitative effects, the effectiveness of the Company’s disclosure controls and procedures and the effectiveness of the Company’s internal control over financial reporting, to differ materially from those expressed in or contemplated by the forward-looking statements. These factors include, without limitation, the risk that additional information may become known prior to the expected filing with the Securities and Exchange Commission of the 2015 Form 10-K or that other subsequent events may occur that would require Bionik to make additional adjustments to its consolidated financial statements. Other risk factors affecting Bionik are discussed in detail in the Company’s filings with the Securities and Exchange Commission, including its Annual Reports on Form 10-K. Bionik undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date:  March 11, 2016